The British Journal of Psychiatry · 1989 · 108 citations · 11 references
MedicinePharmacologyPharmacotherapyClinical PharmacologyNeuropharmacologyPsychopharmacologyAntidepressant PharmacologyAntidepressant PharmacotherapyAntidepressant TherapyDepression ManagementDepression PharmacotherapyPharmacoepidemiologyAntidepressant Drug ClassesAntidepressant EfficacyAntidepressant MedicationsAntidepressant ResponseAntidepressant SafetyAntidepressant TolerabilityMonoamine Oxidase InhibitorsMonoamine Oxidase Involvement
The antidepressant efficacy, tolerability, and safety of moclobemide, a reversible, monoamine oxidase-A inhibitor, were compared with those of imipramine in parallel groups of patients with a major depressive episode, in a 4-week, multicentre (17 centres), randomised study. A total of 381 patients were randomly allocated to either treatment; they were not required to avoid tyramine-rich foods. Drop-out rates were comparable in both groups at about 17%. Judged primarily on the HRSD, no significant differences in efficacy were observed between the groups, but the number of patients presenting with adverse events, as well as the total number of adverse events, was greater with imipramine. Cardiovascular tolerability was satisfactory and physical examination, body weight, and laboratory values were essentially unaffected in both groups.
11
Effects of Iproniazid in Depressive Syndromes
Eric West, Peter Dally · BMJ · 1959 · 382 citations · Full text
Medicine, Pharmacology, Psychiatry +10
Psychopharmacology: A Generation of Progress
Alan L. Krueger · JAMA · 1978 · 294 citations
Monoamine Oxidase Inhibitors, Tyramine, and Cheese
David L. Horwitz, Walter Lovenberg, Karl Engelman et al. · JAMA · 1964 · 229 citations